Zacks Investment Research Downgrades Homology Medicines (FIXX) to Sell
Homology Medicines (NASDAQ:FIXX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “
Other analysts have also recently issued reports about the company. ValuEngine raised Homology Medicines from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Canaccord Genuity assumed coverage on Homology Medicines in a research report on Monday, January 7th. They issued a “buy” rating and a $37.00 price target on the stock. Finally, HC Wainwright assumed coverage on Homology Medicines in a research report on Wednesday, February 20th. They issued a “buy” rating and a $36.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $28.93.
Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.07). Homology Medicines had a negative return on equity of 39.14% and a negative net margin of 1,553.07%. The company had revenue of $0.98 million during the quarter. On average, research analysts predict that Homology Medicines will post -2.18 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc. lifted its position in Homology Medicines by 3.9% in the 4th quarter. TD Asset Management Inc. now owns 24,068 shares of the company’s stock valued at $538,000 after acquiring an additional 900 shares in the last quarter. Citigroup Inc. lifted its position in Homology Medicines by 53.3% in the 4th quarter. Citigroup Inc. now owns 4,180 shares of the company’s stock valued at $93,000 after acquiring an additional 1,453 shares in the last quarter. Legal & General Group Plc lifted its position in Homology Medicines by 103.2% in the 4th quarter. Legal & General Group Plc now owns 3,153 shares of the company’s stock valued at $71,000 after acquiring an additional 1,601 shares in the last quarter. Bank of America Corp DE lifted its position in Homology Medicines by 7.1% in the 4th quarter. Bank of America Corp DE now owns 30,439 shares of the company’s stock valued at $681,000 after acquiring an additional 2,027 shares in the last quarter. Finally, Great West Life Assurance Co. Can bought a new position in Homology Medicines in the 4th quarter valued at approximately $56,000. 60.60% of the stock is currently owned by institutional investors and hedge funds.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.